Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Sickle Cell Disease
Interventions: AG-348; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Nasopharynx Cancer, Sinonasal Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Pembrolizumab, Cetuximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Ann Arbor, Michigan + 1 more

Conditions: Head and Neck Cancer
Interventions: docetaxel, irinotecan hydrochloride; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 43
States / cities: Birmingham, Alabama • Stanford, California • Aurora, Colorado + 33 more

Conditions: Xerostomia, Graft-versus-host-disease, Sjogren's Disease
Interventions: Mesenchymal Stromal Cells (MSC) Dose Level 0, Mesenchymal Stromal Cells (MSC) Dose Level 1; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pneumonia
Interventions: CP-70,429 and PF-03709270; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Heart Transplant Infection Prevention
Interventions: Commercial measles, mumps, and rubella (MMR) vaccine; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 1 Year to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Thrombocytopenia Associated With Liver Disease
Interventions: avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more

Conditions: Long QT Syndrome
Interventions: GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Psoriasis
Interventions: Prurisol, Ziagen; Drug
Lead sponsor: Cellceutix Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Gingival Recession
Interventions: Thin ADM, Thick ADM; Procedure
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Thromboembolism
Interventions: Dabigatran, Warfarin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 2,867 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 18
States / cities: Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more

Conditions: Neurocognitive Impairment, Delirium, Esophageal Cancer, Head and Neck Cancer, Lung Cancer
Interventions: Assessment of therapy complications, Neurocognitive assessment, Quality-of-life assessment; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 4
States / cities: Nashville, Tennessee

Conditions: Oral Mucositis
Interventions: Chemo Mouthpiece, Best Supportive Care only; Device · Other
Lead sponsor: Chemo Mouthpiece; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 11
States / cities: Costa Mesa, California • Goshen, Indiana • Farmington Hills, Michigan + 8 more

Conditions: Dental Plaque, Gingivitis
Interventions: Mouthwash, Floss, Toothbrush, Toothpaste; Drug · Device
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Atypical Facial Pain, Persistent Idiopathic Facial Pain, Atypical Trigeminal Neuralgia, Neuropathic Orofacial Pain, Neuropathic Facial Pain
Interventions: ATNC05, Placebo; Drug
Lead sponsor: Allodynic Therapeutics, Inc; Industry
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Trigeminal Neuralgia
Interventions: Carbon Dioxide Drug Delivery System (CDDS); Drug
Lead sponsor: Capnia, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Tampa, Florida • New York, New York + 3 more

Conditions: Plaque, Gingivitis
Interventions: stannous fluoride toothpaste, cavity protection toothpaste; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Salivary Gland Neoplasms
Interventions: 9-ING-41, Carboplatin; Drug
Lead sponsor: Actuate Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2030 – 2034
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Iron Deficiency, Anaemia in Children
Interventions: Ferric Derisomaltose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: Up to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypersensitivity Reactions
Interventions: Dexamethasone; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Chronic Graft Versus Host Disease Oral
Interventions: Tacrolimus; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year to 40 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions: CTAP101 Capsules, CTAP101 Injection; Drug
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Peoria, Arizona • Evergreen Park, Illinois • Springfield, Massachusetts + 9 more

Conditions: Edentulous or Failing Dentition Mandible
Interventions: TREFOIL concept; Device
Lead sponsor: Nobel Biocare; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia
Interventions: LP-168; Drug
Lead sponsor: Newave Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Durham, North Carolina • Cincinnati, Ohio • Columbus, Ohio + 1 more

Search by objective public record fields.

A Dose-Finding Study of AG-348 in Sickle Cell Disease

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers

Thick vs. Thin Acellular Dermal Matrix (ADM)

Secondary Prevention of Venous Thrombo Embolism (VTE).

Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic

A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis

Comparative Efficacy of Floss and Essential Oil/CPC+Zn Mouthwashes in Reducing Dental Plaque and Gingivitis

Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain

Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia

A Pilot Study to Evaluate a Molecular Method for Plaque

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia

Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity

Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)

Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects

The TREFOIL Concept 5 Year Clinical Investigation

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.